Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
getting the last words in before the big day!
http://archive.fast-edgar.com/20230227/AD25LG2CZ222MZIZ2H2I2Z42AAS2ZC22Z252
kiwi, definitely if Denner wins Germany will be back on the table using a different approach. He's got the experience and connections to maneuver a win.
newman, yup a perfect example is what happened over the weekend with the CEO Union Pacific, activist hf Soroban Capital called for his head. And he was with Union Pacific for 22 yrs.
jroon, yes indeed the COB always pulls the strings. I don't want to sound like a broken record but KM is over his head. KM can play the victim since PWO was his boss. Denner may want to keep him on as he knows where all the moving parts are in the EU. As someone once said to me "you don't have to like the person you work with".
kiwi, I'm not smart enough to trade this stock. I may buy a few more shs if Denner pulls off a win. I think the odds are pretty good that PWO is ousted. If I decided to buy it's for the long term big one which is the BO that should have happened several yrs ago.
GLTA
robin, we'll know tomorrow and logic tells me they know they lost. But their attitude will be life goes on. If it's only PWO who gets the boot I wonder who will become the COB. AD maybe?? the stock will rally for sure if that takes place.....
tatsumaki, yeah and then he moves on to CINC. In January AstraZeneca announced a buy out.
FYI, be prepared peeps...... The results of the proxy contest will likely be announced the same day of the meeting 2/28 during the day some time.... say a few Hail Marys
retinadoc, KM will not resign he wants to hang around cause when the company is sold he stands to vest over 5mill shs of stock. So Sarissa will probably sack the guy and save the company from more dilution. Whereas a departure prior to the company is sold he will receive a package like JT and stay on as a consultant for a certain period of time.
TTE, please explain the awards you mentioned. I don't understand. Is that in the charter or somewhere else... they can't just issue options or RSU's on demand.
Rose, you're correct in one of Sarissa's PR's made reference to that possibility if amarin didn't start generating revs from the EU.
megc, that's why the stock on the NASDAQ trades with ADR's =American Depositary Receipts cause their charter is in the UK and is foreign.
https://www.marketwatch.com/investing/stock/amrn
nukem, re your last sentence, if Amarin goes after Sarissa with any kind of lawsuit, Amarin will run out of cash defending themselves. That would be a friggin mess.
I'm not jumping to any conclusions till we get the final count. I'm hoping we have a quorum on Tuesday to move forward with the next phase whatever that may be. If no quorum then another general meeting will be called and more of the shareholder's cash will be spent all over again.
Michael, it can be any where btw 2 to 4 days but their earnings date is march 1. So I'm thinking they will announce at cc on 3.1.
jroon, I understand the whole compensation rule based on the DEF 14 filing. But why wait till the middle of the night and after the votes to file?
birdrock, PWO et al waited till the 11th hour before filing their options and RSU. More dilution and once again slimy move after the window closes for voting.
meowzo, machine learning
jasbg, with all due respect. The price action is not related to anything other than a channel the stock has been in for a while. I'm curious to see how the stock responds after 2/28 votes are disclosed. Denner has a long road ahead to change the trajectory of the company he needs to right side the company in order for the outcome to be successful.
Actually, several blocks 200,000 and over traded during hours. Nice
156,850 block trades at the close on the uptick! Good sign.
doing some research on Eddingpharm the link below is a fairly recent IPO that was canceled Feb 3, 2023. Doesn't look good peeps.
https://pitchbook.com/profiles/company/52763-86#overview
robin, Did you call the law firm to confirm that outsider shareholders are permitted? Because it's not public information that will be disclosed I wonder if they'll go into closed doors to complete the vote count?
Tatsum,
Yup at the time when JZ was selling stock into the market was about the time I discovered vascepa. I wish I knew more at the time who the players were. Insider selling usually sends up a red flag but wasn't that involved to care.
funnygi, actually JZ was right but that was back then. Here we are with a very expensive inventory. The contracts with suppliers have been renegotiated but too little too late.
If Denner wins the proxy contest I wonder what his plans would be to alleviate the excess and right side the financials.
ramfan, agreed. We've known for over 2 yrs that Hikma's has all intentions of infringing on the CVD market. And if they find a supply that's exactly what they will do. In hindsight locking up the supply with anticipation of a huge market prior to Duaster made all the sense. But now this inventory is a wasting asset on their balance sheet unless they due a branded GV.
We need BP to take the reins I will say the rosary every day till the results of the GM are disclosed.
Tal, Any thoughts on this latest BS from Hikma?
Hikma accuses Amarin of suppressing generic versions of heart pill
REUTERS 4:50 PM ET 2/22/2023
Symbol Last Price Change
AMRN 1.82up +0.02 (+1.1111%)
QUOTES AS OF 04:00:00 PM ET 02/22/2023
*
Hikma claims Amarin(AMRN) used exclusive agreements with suppliers to frustrate generic rivals
*
Dr. Reddy's filed similar lawsuit in 2021
By Brendan Pierson
(Reuters) - Generic drugmaker Hikma Pharmaceuticals USA Inc has sued Amarin Pharma Inc, accusing it of using illegal tactics to delay generic competition for its heart drug Vascepa.
In a complaint filed Tuesday in Trenton, New Jersey federal court, Hikma claimed that Amarin(AMRN) "deliberately and meticulously locked up the supply" of the key ingredient needed to make generic Vascepa in order to maintain a monopoly.
London-based Hikma eventually launched the first generic version of Vascepa in November 2020, but it said that Amarin's(AMRN) tactics delayed the launch by months, and initially prevented Hikma from supplying enough of its generic to compete meaningfully with the branded version.
New Jersey-based Amarin(AMRN) did not immediately respond to a request for comment. The company was already facing a similar lawsuit filed in 2021 in the same court by Indian generic drugmaker Dr. Reddy's Laboratories Ltd, which remains pending.
Vascepa, derived from fish oil, is approved by the U.S. Food and Drug Administration to lower so-called "bad" cholesterol and reduce the risk of cardiovascular disease generally. It is Amarin's(AMRN) only product.
The drug brought Amarin(AMRN)$598 million in 2020, but sales have since fallen as generics have entered the market, forcing the company to cut its workforce last year. The company said in a 2020 statement to investors that Vascepa had been prescribed more than 8 million times since its 2013 U.S. launch.
Amarin (AMRN) initially sought to block competitors by suing Hikma and Dr. Reddy's for patent infringement after they sought FDA approval to sell generic versions of the drug, but lost after a Nevada judge ruled its patents obvious. The U.S. Supreme Court in 2021 rejected Amarin's(AMRN) bid to revive the patents.
Hikma said that even after losing the patent case, Amarin(AMRN) held on to its monopoly by entering into exclusive agreements with suppliers of the active ingredient, icosapent ethyl, that prevented the suppliers from selling to any other companies.
Hikma called the agreements an "illegal anticompetitive strategy to prevent, delay, and frustrate generic competition and maintain its monopoly power and prices for Vascepa" and said it ran afoul of the federal Sherman Act and New Jersey antitrust law.
The case is Hikma Pharmaceuticals USA Inc v. Amarin Pharma Inc, U.S. District Court for the District of New Jersey, No. 3:23-cv-01016.
For Hikma: Charles Klein of Winston & Strawn and others
For Amarin(AMRN): not available
Read more:
U.S. Supreme Court denies Amarin's(AMRN) bid to revive Vascepa drug patents
Amarin (AMRN) to slash jobs as generic rivals dull U.S. prospects of heart drug (Reporting By Brendan Pierson in New York; editing by Alexia
MMS, the trick is to cc Sarissa or Denner I usually receive a reply within a day or two. But since I sent them a not so nice email about the crumpy job they did when updating the website I doubt I'll ever hear from them again. Also, when I complained I cc Denner.
jfmcrr, yeah for you. You got it done. If you're feeling left out you can always attend an IHub group meeting.
capt, you're very talented love all your artwork. You should forward this to adenner@sarissacap.com or info@sarissacap.com.
Jfmcrr, didn't you request a proxy from your brokerage firm?
robin, sounds like a sayonara letter to me. LOL
megc, ADR/ADS shares have the same voting rights. I suspect the balance of shares that were mentioned in the last correspondence was voted in 2 separate tranches. But regardless the beneficial ownership between Sarissa and Dr. Sterling totals 25,210,000.
I still have questions about the Morgan Stanley 13D filing increasing their holdings by 16mill shares in one qtr. Let's hope they voted BLUE.
megc, ADR/ADS shares have the same voting rights. I suspect the balance of shares that were mentioned in the last correspondence were voted in 2 separate tranches. But regardless the beneficial ownership between Sarissa and Dr. Sterling totals 25,210,000.
I still have questions about the Morgan Stanley 13D filing increasing their holdings by 16mill shares in one qtr. Let's hope they voted BLUE.
birdrock, FYI, re GM. Sarissa's representative, a D.F. King representative along with outside counsel will ALL be in attendance on the 28th.
birdrock, IIRC there was another interview with Melissa Lee where JT said those infamous words "it works" he may have used the words patent fortress not sure as that would be a bit promotional for JT I don't think that wasn't his style.
rose, lol since I put him on ignore it was through a third party poster where I read Punta something I didn't pay much attention to it. But you're correct the peeps who decided to vote white aren't posting much anymore. LOL
rose, are you referring to someone who's basking in the sun in punta gorda?
bird, who votes the shared voting rights shares?
please see below which is the last correspondence re the Sarissa proxy, I wonder what happened to the additional 5mill plus shs they own?
From: Caroline Hall <Caroline.Hall@dfkingltd.co.uk>
Sent: 14 February 2023 17:22
To: Hewitt, Adam <Adam.Hewitt@equiniti.com>; Taylor, Jamie-Leah <Jamie-Leah.Taylor2@equiniti.com>
Cc: Viraj Patel <viraj.patel@dfkingltd.co.uk>
Subject: Amarin GM—Sarissa signed proxy card attached—please review
Importance: High
CAUTION: This email originated from outside the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.
Hello Adam, Jamie-Leah,
Please see attached the completed proxy cards for the 8 funds held by Sarissa on the ordinary register (totalling 20,300,000 shares).
Can you please confirm that these are acceptable so that orginals can be couried over to Aspect house for your attention.
Thank you
Caroline